Preferred Label : Duvortuxizumab;
NCIt synonyms : CD19 x CD3 DART Protein JNJ-64052781; hBU12(2.4)-hXR32-MP3 M1.2;
NCIt definition : An anti-CD19/anti-CD3 bispecific, humanized antibody-like protein, with potential
immunostimulatory and antineoplastic activities. Duvortuxizumab possesses two antigen-recognition
and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins
that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated
antigen (TAA) overexpressed on the surface of B-cells. Upon administration, duvortuxizumab
binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking
CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result
in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell
specific membrane antigen, is expressed during normal B-cell development and on B-cell
malignancies.;
UNII : J545GSE96Y;
CAS number : 1831098-91-9;
Molecule name : JNJ-64052781; MGD011; RES192M1.2;
Origin ID : C122406;
UMLS CUI : C4724811;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
